BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

266 related articles for article (PubMed ID: 28125857)

  • 1. New bismuth-containing quadruple therapy in patients infected with Helicobacter pylori: A first Italian experience in clinical practice.
    Tursi A; Di Mario F; Franceschi M; De Bastiani R; Elisei W; Baldassarre G; Ferronato A; Grillo S; Landi S; Zamparella M; De Polo M; Boscariolo L; Picchio M
    Helicobacter; 2017 Jun; 22(3):. PubMed ID: 28125857
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A real life study of Helicobacter pylori eradication with bismuth quadruple therapy in naïve and previously treated patients.
    Gómez Rodríguez BJ; Castro Laria L; Argüelles Arias F; Castro Márquez C; Caunedo Álvarez Á; Romero Gómez M
    Rev Esp Enferm Dig; 2017 Aug; 109(8):552-558. PubMed ID: 28617030
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effectiveness and Safety of Pylera® in Patients Infected by Helicobacter Pylori: A Multicenter, Retrospective, Real Life Study.
    Tursi A; Franceschi M; Allegretta L; Savarino E; De Bastiani R; Elisei W; Baldassarre G; Ferronato A; Scida S; Miraglia C; Penna A; Licci C; Rizzo GL; Pranzo G; Cassieri C; Brandimarte G; Picchio M; Di Mario F
    Dig Dis; 2018; 36(4):264-268. PubMed ID: 29669354
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rescue therapy with bismuth-containing quadruple therapy in patients infected with metronidazole-resistant Helicobacter pylori strains.
    Muller N; Amiot A; Le Thuaut A; Bastuji-Garin S; Deforges L; Delchier JC
    Clin Res Hepatol Gastroenterol; 2016 Sep; 40(4):517-24. PubMed ID: 26850363
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bismuth-based quadruple therapy following H. pylori eradication failures: a multicenter study in clinical practice.
    Zullo A; De Francesco V; Bellesia A; Vassallo R; D'Angelo A; Scaccianoce G; Sacco R; Bresci G; Eramo A; Tanzilli A; Ridola L; Alvaro D; Londoni C; Brambilla G; Manta R; Di Ciaula A; Portincasa P
    J Gastrointestin Liver Dis; 2017 Sep; 26(3):225-229. PubMed ID: 28922433
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The "three-in-one" formulation of bismuth quadruple therapy for Helicobacter pylori eradication with or without probiotics supplementation: Efficacy and safety in daily clinical practice.
    Zagari RM; Romiti A; Ierardi E; Gravina AG; Panarese A; Grande G; Savarino E; Maconi G; Stasi E; Eusebi LH; Farinati F; Conigliaro R; Bazzoli F; Romano M
    Helicobacter; 2018 Aug; 23(4):e12502. PubMed ID: 29924430
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Randomized Clinical Trial: Esomeprazole, Bismuth, Levofloxacin, and Amoxicillin or Cefuroxime as First-Line Eradication Regimens for Helicobacter pylori Infection.
    Fu W; Song Z; Zhou L; Xue Y; Ding Y; Suo B; Tian X; Wang L
    Dig Dis Sci; 2017 Jun; 62(6):1580-1589. PubMed ID: 28391418
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effectiveness and safety of repeated quadruple therapy in Helicobacter pylori infection after failure of second-line quadruple therapy: repeated quadruple therapy as a third-line therapy.
    Lee SK; Lee SW; Park JY; Kwon BS; Kim SY; Hyun JJ; Kim JH; Jung SW; Koo JS; Yim HJ; Choi JH
    Helicobacter; 2011 Oct; 16(5):410-4. PubMed ID: 21923688
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Annual eradication rate of bismuth-containing quadruple therapy as second-line treatment for Helicobacter pylori infection: A 15-year prospective study at a tertiary hospital in Korea.
    Yoon K; Kim N; Lee JW; Yoon H; Shin CM; Park YS; Lee DH
    Helicobacter; 2020 Jun; 25(3):e12685. PubMed ID: 32141173
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Use of a combination formulation of bismuth, metronidazole and tetracycline with omeprazole as a rescue therapy for eradication of Helicobacter pylori.
    Delchier JC; Malfertheiner P; Thieroff-Ekerdt R
    Aliment Pharmacol Ther; 2014 Jul; 40(2):171-7. PubMed ID: 24863854
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Twice-a-day bismuth-containing quadruple therapy for Helicobacter pylori eradication: a randomized trial of 10 and 14 days.
    Dore MP; Farina V; Cuccu M; Mameli L; Massarelli G; Graham DY
    Helicobacter; 2011 Aug; 16(4):295-300. PubMed ID: 21762269
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of sequential therapy and amoxicillin/tetracycline containing bismuth quadruple therapy for the first-line eradication of Helicobacter pylori: a prospective, multi-center, randomized clinical trial.
    Lee JY; Kim N; Park KS; Kim HJ; Park SM; Baik GH; Shim KN; Oh JH; Choi SC; Kim SE; Kim WH; Park SY; Kim GH; Lee BE; Jo Y; Hong SJ
    BMC Gastroenterol; 2016 Jul; 16(1):79. PubMed ID: 27460100
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rescue therapy with bismuth quadruple regimen in patients with Helicobacter pylori -resistant strains.
    Fiorini G; Saracino IM; Zullo A; Gatta L; Pavoni M; Vaira D
    Helicobacter; 2017 Dec; 22(6):. PubMed ID: 29094477
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pylera and sequential therapy for first-line Helicobacter pylori eradication: a culture-based study in real clinical practice.
    Fiorini G; Zullo A; Saracino IM; Gatta L; Pavoni M; Vaira D
    Eur J Gastroenterol Hepatol; 2018 Jun; 30(6):621-625. PubMed ID: 29481383
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Quadruple, sequential, and concomitant first-line therapies for H. pylori eradication: a prospective, randomized study.
    De Francesco V; Pontone S; Bellesia A; Serviddio G; Panetta C; Palma R; Zullo A
    Dig Liver Dis; 2018 Feb; 50(2):139-141. PubMed ID: 29089267
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Limited effectiveness with a 10-day bismuth-containing quadruple therapy (Pylera
    Rodríguez de Santiago E; Martín de Argila de Prados C; Marcos Prieto HM; Jorge Turrión MÃ; Barreiro Alonso E; Flores de Miguel A; de la Coba Ortiz C; Rodríguez Escaja C; Pérez Álvarez G; Ferre Aracil C; Aguilera Castro L; García García de Paredes A; Rodríguez Pérez A; Albillos Martínez A
    Helicobacter; 2017 Oct; 22(5):. PubMed ID: 28771880
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The efficacy of bismuth containing quadruple therapy as a first-line treatment option for Helicobacter pylori.
    Uygun A; Kadayifci A; Safali M; Ilgan S; Bagci S
    J Dig Dis; 2007 Nov; 8(4):211-5. PubMed ID: 17970879
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Current Status of Five Different Regimens for Empiric First-Line Helicobacter pylori Eradication in Turkey.
    Gungor G; Baglıcakoglu M; Kayacetin E; Biyik M; Ucar R; Goktepe H; Ataseven H; Demir A
    Digestion; 2015; 92(2):55-9. PubMed ID: 26183105
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Eradication Rate of
    Liu RP; Romero R; Sarosiek J; Dodoo C; Dwivedi AK; Zuckerman MJ
    South Med J; 2018 Jan; 111(1):51-55. PubMed ID: 29298370
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fourteen- vs seven-day bismuth-based quadruple therapy for second-line Helicobacter pylori eradication.
    Hwang JJ; Lee DH; Lee AR; Yoon H; Shin CM; Park YS; Kim N
    World J Gastroenterol; 2015 Jul; 21(26):8132-9. PubMed ID: 26185386
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.